论文部分内容阅读
目的:观察奈达铂(NDP)、替加氟(Ft-207)联合紫杉醇(PTx)治疗晚期食管癌的近期疗效及安全性。方法:选择2008年3月至2010年6月在我院治疗的65例晚期食管癌患者,应用NDP 20 mg/m2,静脉滴注,第1～3天;Ft～207 500 mg/m2,静脉滴注射,第1～5天;PTx 135～175 mg/m2,静脉滴注,第1天;21天为1个周期,至少2个周期后评价疗效和毒副反应的发生情况。结果:除1例因奈达铂过敏反应停药外,共64例患者完成化疗并可评价疗效。该方案总体有效率(RR)为56.3%,其中完全缓解(CR)3例(占4.7%),部分缓解(PR)33例(占51.6%),病情稳定(SD)17例(占26.6%),另有11例(占17.2%)出现不同程度的疾病进展(PD)。仅1例出现可控制的IV度骨髓抑制。结论:NDP、Ft-207联合PTx对晚期食管癌近期疗效肯定,安全性好,值得临床推广应用。
Objective: To observe the short-term efficacy and safety of nedaplatin (NDP), tegafur (Ft-207) combined with paclitaxel (PTx) in the treatment of advanced esophageal cancer. METHODS: Sixty-five patients with advanced esophageal cancer who were treated in our hospital from March 2008 to June 2010 were selected and treated with NDP 20 mg/m 2 intravenous drip for 1 to 3 days; Ft ~ 207 500 mg/m 2 intravenous Droplet injection, 1st to 5th day; PTx 135-175 mg/m2, intravenous drip on the 1st day; 21 days on 1 cycle, at least 2 cycles after the evaluation of efficacy and side effects of toxicity. Results: A total of 64 patients completed chemotherapy and evaluated the efficacy, except for one case of nedaplatin allergy. The total effective rate (RR) of the protocol was 56.3%, including complete remission (CR) in 3 patients (4.7%), partial remission (PR) in 33 patients (51.6%), and stable condition (SD) in 17 patients (26.6%). ) Another 11 patients (17.2%) experienced varying degrees of disease progression (PD). Only 1 patient had a controlled IV degree myelosuppression. Conclusion: NDP, Ft-207 combined with PTx is effective for the treatment of advanced esophageal cancer. It has good safety and is worthy of clinical application.